Current evidence indicates that the emergency-use approval of recombinant mAbs that bind to the viral trimeric S-protein and prevent binding to the host receptor angiotensin-converting enzyme 2 (ACE2) have had a preliminary clinical impact in limiting the development of severe COVID-19 when administered during the early onset of infection [4,5]. This evidence concerns the gene ACE2 and COVID-19.